

ECDC Project synopsis

Estimating the burden of tuberculosis infection in the EU/EEA (2024-2027)

Background

- TB infection (TBI) prevalence has been estimated for Europe, at 11- 15% 1,2.
- Country-specific TBI estimates are not available for Member States of the European Union/European Economic Area.
- Available TBI estimates for specific at-risk populations are 'fragmented'.

Relevance

Country-level evidence would better support the development of policy to ensure availability of TB preventative treatment (TPT) to manage TB infection and progression to TB disease.

Project Purpose

The scope of this project is to estimate the prevalence of tuberculosis (TB) infection and rate of progression to active TB in at-risk groups among selected countries in the EU/EEA.

Project Objectives

- 1. To assess the feasibility of generating these estimates in each country of the EU/EEA;
- 2. To estimate TBI prevalence and rate of progression to active TB in at-risk groups for 6 -9 EU/EEA countries selected based on feasibility;
- 3. To present TBI prevalence and rate of progression to active to TB in at-risk groups at the national level;
- 4. To identify key challenges around TBI management and action points for ECDC consideration.


At-risk populations of interest

- Household and close contacts
- Immigrants and asylum seekers
- People with underlying medical conditions
- Homeless populations
- Additional country-specific risk populations

¹ Houben RMGJ, Dodd PJ (2016) The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med 13(10): e1002152. https://doi.org/10.1371/journal.pmed.1002152


² Guthmann JP, Haas W. Tuberculosis in the European Union/European Economic Area: much progress, still many challenges. Euro Surveill. 2019 Mar;24(12):1900174. doi: 10.2807/1560-7917.ES.2019.24.12.1900174. PMID: 30914075; PMCID: PMC6440586.

Methodological Approach





Selection of maximum 9 EU/EEA countries based on feasibility assessment If >9 countries are eligible for phase 2, geography, population size, and TB burden will be taken into account for the final selection.



Project Outputs

Phase 1: Feasibility assessment

- Overall report
- Country-specific reports
- Manuscript TBD

Phase 2: TBI prevalence estimates

- Overall report
- Country-specific reports
- Manuscript

Country Benefits

Participating countries will benefit by having estimates on TBI prevalence and rate of progression to TB disease, and knowledge and experience to update these estimates when there are changes in at-risk populations, or risk factors.

(2024-2027) 2/3

Project Consortium



Consortium lead

Christina Mergenthaler (Epidemiologist)

Dr. Mirjam Bakker (Senior epidemiologist)

Jake Mathewson (Project manager)



Dr. Ineke Spruijt

(Senior TB consultant & Epidemiologist)

Dr. Christiaan Mulder (Senior Epidemiologist)

Jozefien Groenendijk

(Junior Researcher)



Prof. Dr. Frank Cobelens

(Professor of Global Health & Senior Fellow)

Dr. Sabine Hermans

(Physician & Senior Epidemiologist)



Prof. Dr. Pete Dodd (TB modeller)

(2024-2027)3/3